NVCT
Nuvectis Pharma Inc
21.60$
+2.7%
vs. previous close
Closing price · As of: Sep 24, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | -100.0% | – | – | – | – | – | – | |
| – | +78.1% | -59.9% | +5.6% | -6.1% | +207.4% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -4.9% | -37.6% | +10.6% | -4.2% | +59.5% | -18.1% | -1.8% | +59.8% | -11.9% | -19.3% | +14.1% | – | |
| – | +55.6% | -33.3% | -2.1% | -9.4% | +26.8% | -3.3% | +57.9% | -32.3% | +25.3% | -14.9% | +16.7% | – | |
| – | +11.5% | -36.0% | +5.6% | -6.1% | +47.9% | -13.7% | +18.4% | +18.2% | -2.3% | -17.8% | +15.0% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | -100.0% | -4,427.7% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: September 24, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.